pCODR Deliberative Framework
The pCODR Deliberative Framework is a structured approach used to assess cancer drugs in Canada, focusing on clinical benefits, cost, patient perspectives, and real-world healthcare impacts. It ensures decisions are made with input from patients, clinicians, and decision-makers.
At a glance
Use when
Assessing the value and reimbursement potential of new oncology drugs in public healthcare systems
Avoid when
Evaluating non-oncology technologies or in settings where rapid assessment without broad stakeholder input is required
Inputs
Clinical trial data, economic models, patient input, real-world evidence, expert opinion
Outputs
Recommendations for public reimbursement of oncology drugs, including conditions for use and evidence gaps
How it works
The pCODR Deliberative Framework evaluates oncology drugs through a transparent, multi-criteria decision-making process that integrates clinical evidence, economic analysis, patient input, and expert committee deliberation. It was developed to support provincial reimbursement decisions and was integrated into CADTH to align with national HTA processes while maintaining stakeholder engagement best practices.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation, Patient and Social Aspects
- Categories
- AppraisalContext & ImplementationRWE
- Assumptions
- That stakeholder engagement improves decision legitimacy; that incremental clinical benefit can be meaningfully assessed; and that contextual factors (e.g., patient values, system capacity) are critical to adoption decisions
- Strengths
- Strong stakeholder engagement, transparent deliberative process, integration of patient perspectives, contextual relevance to Canadian provinces
- Limitations
- Limited generalizability outside oncology; complexity in balancing diverse stakeholder views; potential delays due to extensive consultation
- Also known as
- pan-Canadian Oncology Drug Review Framework, pCODR Framework
Questions this answers
- › Does the drug provide meaningful clinical benefit for cancer patients?
- › Is the drug cost-effective within the Canadian healthcare context?
- › How do patient experiences and values influence the drug's value?
- › How does the drug impact healthcare systems and clinical practice?
- › Are there equity or access considerations for different patient populations?
- › What uncertainties exist in the evidence and how should they be addressed in decision-making?
References & sources
Similar by meaning
Beta record. Based on the original catalogue summary; primary-source enrichment pending.